Parkinson Disease Clinical Trials in New York, New York

15 studies are recruiting for parkinson disease in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

   A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Site-005, New York, New York

   Locations

   22 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06976268 on ClinicalTrials.gov

2. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

   This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. P…

   Stage

   Phase 2

   Ages

   30 to 80

   Site

   Joan and Sanford I. Weill Department of Medicine (Site #224), New York, New York

   Locations

   30 in total

   Run by

   Appello Pharmaceuticals, Inc.

   See if you can join NCT07432958 on ClinicalTrials.gov

3. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

   The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic p…

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Icahn School of Medicine at Mount Sinai/Mount Sinai West, New York, New York

   Locations

   72 in total

   Run by

   Neuron23 Inc.

   See if you can join NCT06680830 on ClinicalTrials.gov

4. Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms

   Young Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger indi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT07752355 on ClinicalTrials.gov

5. Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

   A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Weill Cornell Medical College, New York, New York

   Locations

   5 in total

   Run by

   Hillhurst Biopharmaceuticals, Inc.

   See if you can join NCT07005180 on ClinicalTrials.gov

6. Autoimmune Features of Neurodegenerative Disorders

   This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD/Amnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immu…

   Stage

   Not phased

   Ages

   55 to 90

   Site

   Columbia University Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT04239079 on ClinicalTrials.gov

7. Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

   This is a pilot randomized, sham-controlled, double-blind, multi-center study evaluating the safety and preliminary effectiveness of the Gen0Bh Transcranial Focused Ultrasound System for the treatment of motor symptoms in individuals with idiopathic Parkinson's disease.

   Stage

   Not phased

   Ages

   22 to 80

   Site

   Radial Midtown Manhattan, New York, New York

   Locations

   4 in total

   Run by

   Sanmai Technologies PBC dba Sanmai

   See if you can join NCT07207122 on ClinicalTrials.gov

8. PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

   The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest…

   Stage

   Not phased

   Ages

   30 and older

   Site

   Beth Israel Medical Center, New York, New York

   Locations

   50 in total

   Run by

   Michael J. Fox Foundation for Parkinson's Research

   See if you can join NCT04477785 on ClinicalTrials.gov

9. A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

   The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

   Stage

   Phase 2

   Ages

   45 to 75

   Site

   Columbia University, New York, New York

   Locations

   46 in total

   Run by

   AskBio Inc

   See if you can join NCT06285643 on ClinicalTrials.gov

10. Natural History Study of Synucleinopathies

    Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of moveme…

    Stage

    Not phased

    Ages

    18 and older

    Site

    NYU Medical Center, New York, New York

    Locations

    8 in total

    Run by

    NYU Langone Health

    See if you can join NCT01799915 on ClinicalTrials.gov

11. Parkinson's Disease Biomarkers in Nerve Cells in the Gut

    Parkinson's disease affects all the nerve cells in the body, including the ones in the gut. The gut contains its own nervous system, the enteric nervous system, and can be thought of as a "second brain". This second brain can reflect what is going on in the actual brain. This study is being done to…

    Stage

    Not phased

    Ages

    45 to 75

    Site

    Weill Cornell Medicine, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT05347407 on ClinicalTrials.gov

12. This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

    This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

    Stage

    Phase 1

    Ages

    30 to 75

    Site

    Cornell University Weill Medical College, New York, New York

    Run by

    iRegene Therapeutics Co., Ltd.

    See if you can join NCT07102342 on ClinicalTrials.gov

13. Rehabilitation of Airway Protection in Parkinson's Disease

    Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical defi…

    Stage

    Phase 2

    Ages

    50 to 90

    Site

    Teachers College, Columbia University, New York, New York

    Locations

    2 in total

    Run by

    Teachers College, Columbia University

    See if you can join NCT05700825 on ClinicalTrials.gov

14. NYSCF Scientific Discovery Biobank

    The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store th…

    Stage

    Not phased

    Ages

    0 and older

    Site

    New York Stem Cell Foundation Research Institute, New York, New York

    Run by

    New York Stem Cell Foundation Research Institute

    See if you can join NCT06203106 on ClinicalTrials.gov

15. Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease

    The goal of this clinical trial is to learn whether noise-augmented feedback using automatic speech recognition improves intelligibility and social participation in individuals with Parkinson's disease. The main questions the investigators will address are: Does noise-augmented feedback lead to inc…

    Stage

    EARLY_Phase 1

    Ages

    50 to 80

    Site

    Teachers College, Columbia University, New York, New York

    Run by

    Teachers College, Columbia University

    See if you can join NCT06540989 on ClinicalTrials.gov